📣 VC round data is live. Check it out!
- Public Comps
- Actuate Therapeutics
Actuate Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Actuate Therapeutics and similar public comparables like Intervacc, Kala Bio, Nicox, Estrella Immunopharma and more.
Actuate Therapeutics Overview
About Actuate Therapeutics
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Founded
2015
HQ

Employees
10
Website
Financials (LTM)
EV
$52M
Valuation Multiples
Start free trialActuate Therapeutics Financials
Actuate Therapeutics reported last 12-month revenue of -.
In the same LTM period, Actuate Therapeutics generated had net loss of ($23M).
Revenue (LTM)
Actuate Therapeutics P&L
In the most recent fiscal year, Actuate Therapeutics reported revenue of - and EBITDA of ($22M).
Actuate Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
Actuate Therapeutics Stock Performance
Actuate Therapeutics has current market cap of $45M, and enterprise value of $52M.
Market Cap Evolution
Actuate Therapeutics' stock price is $1.88.
Actuate Therapeutics share price decreased by 6.9% in the last 30 days, and by 67.9% in the last year.
Actuate Therapeutics has an EPS (earnings per share) of $-0.93.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $52M | $45M | -5.1% | -6.9% | -31.4% | -67.9% | $-0.93 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialActuate Therapeutics Valuation Multiples
Actuate Therapeutics trades at (2.3x) EV/EBITDA.
Actuate Therapeutics Financial Valuation Multiples
As of June 3, 2026, Actuate Therapeutics has market cap of $45M and EV of $52M.
Actuate Therapeutics has a P/E ratio of (2.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Actuate Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Actuate Therapeutics Margins & Growth Rates
Actuate Therapeutics grew net profit by 4% in the last fiscal year.
Actuate Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Actuate Therapeutics Operational KPIs
Actuate Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.3M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Actuate Therapeutics Competitors
Actuate Therapeutics competitors include Intervacc, Kala Bio, Nicox, Estrella Immunopharma, Mira Pharmaceuticals, Oncocross, J. Molner, Gossamer Bio, Ascelia Pharma and Vivoryon Therapeutics.
Most Actuate Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 12.3x | 13.6x | (5.2x) | (4.6x) | |||
| - | - | (1.6x) | - | |||
| 2.1x | - | 1.9x | - | |||
| - | - | (3.4x) | - | |||
| - | - | (3.2x) | - | |||
| 125.6x | - | (6.1x) | - | |||
| 32.8x | - | 43.3x | - | |||
| 3.1x | 3.5x | (1.0x) | (1.1x) | |||
This data is available for Pro users. Sign up to see all Actuate Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Actuate Therapeutics VC Funding History
Before going public, Actuate Therapeutics raised $65M in total equity funding, across 5 rounds.
Actuate Therapeutics Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Actuate Therapeutics
| When was Actuate Therapeutics founded? | Actuate Therapeutics was founded in 2015. |
| Where is Actuate Therapeutics headquartered? | Actuate Therapeutics is headquartered in United States. |
| How many employees does Actuate Therapeutics have? | As of today, Actuate Therapeutics has over 10 employees. |
| Who is the CEO of Actuate Therapeutics? | Actuate Therapeutics' CEO is Daniel M. Schmitt. |
| Is Actuate Therapeutics publicly listed? | Yes, Actuate Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Actuate Therapeutics? | Actuate Therapeutics trades under ACTU ticker. |
| When did Actuate Therapeutics go public? | Actuate Therapeutics went public in 2024. |
| Who are competitors of Actuate Therapeutics? | Actuate Therapeutics main competitors include Intervacc, Kala Bio, Nicox, Estrella Immunopharma, Mira Pharmaceuticals, Oncocross, J. Molner, Gossamer Bio, Ascelia Pharma, Vivoryon Therapeutics. |
| What is the current market cap of Actuate Therapeutics? | Actuate Therapeutics' current market cap is $45M. |
| Is Actuate Therapeutics profitable? | No, Actuate Therapeutics is not profitable. |
| What is the current net income of Actuate Therapeutics? | Actuate Therapeutics' last 12 months net income is ($23M). |
| How many companies Actuate Therapeutics has acquired to date? | Actuate Therapeutics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Actuate Therapeutics has invested to date? | Actuate Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Actuate Therapeutics
Lists including Actuate Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.